Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?

Mov Disord. 2000 Nov;15(6):1279-81. doi: 10.1002/1531-8257(200011)15:6<1279::aid-mds1040>3.0.co;2-4.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Drug Therapy, Combination
  • Drug Tolerance
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Neuromuscular Agents / pharmacology
  • Neuromuscular Agents / therapeutic use*
  • Severity of Illness Index
  • Torticollis / drug therapy*
  • Treatment Failure

Substances

  • Immunoglobulins, Intravenous
  • Neuromuscular Agents
  • Botulinum Toxins, Type A